Bone Biotech PolyPid Ltd. Files For A $24 Million IPO
PolyPid, an early stage drug delivery biotech developing an antibiotic coating for bone repair, filed on Tuesday with the SEC to raise up to $24 million in an initial public offering.
PolyPid's two lead candidates, BonyPid-1000 and BonyPid-500, combat bacterial infection around implanted bone substitutes (for open bone fractures) and around dental implants by coating the bone substitute with an antibiotic that uses its proprietary drug delivery technology.
Help employers find you! Check out all the jobs and post your resume.
PolyPid's two lead candidates, BonyPid-1000 and BonyPid-500, combat bacterial infection around implanted bone substitutes (for open bone fractures) and around dental implants by coating the bone substitute with an antibiotic that uses its proprietary drug delivery technology.
Help employers find you! Check out all the jobs and post your resume.